Home LiteratureArticle Details
PMID: 25534622 Published · ppublish English Journal Article Review

Clinical blockade of PD1 and LAG3--potential mechanisms of action.

Nature reviews. Immunology ·Vol. 15 ·No. 1 ·2015-01-00 ·Pages 45-56

Nguyen LT, Ohashi PS

Abstract

Dysfunctional T cells can render the immune system unable to eliminate infections and cancer. Therapeutic targeting of the surface receptors that inhibit T cell function has begun to show remarkable success in clinical trials. In this Review, we discuss the potential mechanisms of action of the clinical agents that target two of these receptors, programmed cell death protein 1 (PD1) and lymphocyte activation gene 3 protein (LAG3). We also suggest correlative studies that may define the predominant mechanisms of action and identify predictive biomarkers.

MeSH Terms
Animals Antibodies, Monoclonal/pharmacology,therapeutic use Antigens, CD/metabolism Costimulatory and Inhibitory T-Cell Receptors/antagonists & inhibitors Humans Ligands Molecular Targeted Therapy Programmed Cell Death 1 Receptor/antagonists & inhibitors,metabolism Protein Binding T-Lymphocytes/drug effects,immunology,metabolism
Chemicals
Antibodies, Monoclonal Antigens, CD CD223 antigen Costimulatory and Inhibitory T-Cell Receptors Ligands Programmed Cell Death 1 Receptor
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Nguyen Linh T
Immune Therapy Program, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, Ontario, M5G 2M9, Canada.
Ohashi Pamela S
Immune Therapy Program, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, Ontario, M5G 2M9, Canada.
References (123)
123 references, click to expand
  1. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
    Nature. 2014 Nov 27;515(7528):563-7 PMID: 25428504
  2. Nivolumab plus ipilimumab in advanced melanoma.
    N Engl J Med. 2013 Jul 11;369(2):122-33 PMID: 23724867
  3. Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells in vivo.
    Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):10468-73 PMID: 22689978
  4. Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization.
    PLoS One. 2012;7(2):e30852 PMID: 22347406
  5. Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells.
    Eur J Immunol. 2005 Jul;35(7):2081-8 PMID: 15971272
  6. Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection.
    Nat Med. 2010 Apr;16(4):452-9 PMID: 20208540
  7. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
    EMBO J. 1992 Nov;11(11):3887-95 PMID: 1396582
  8. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination.
    J Clin Invest. 2010 Jan;120(1):157-67 PMID: 20038811
  9. PD-1 dependent exhaustion of CD8+ T cells drives chronic malaria.
    Cell Rep. 2013 Dec 12;5(5):1204-13 PMID: 24316071
  10. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.
    Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875-80 PMID: 20385810
  11. Role played by the programmed death-1-programmed death ligand pathway during innate immunity against Mycobacterium tuberculosis.
    J Infect Dis. 2010 Aug 15;202(4):524-32 PMID: 20617899
  12. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis.
    J Immunol. 2011 May 1;186(9):5173-83 PMID: 21441454
  13. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection.
    J Exp Med. 2006 Oct 2;203(10):2281-92 PMID: 16954372
  14. B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism.
    J Exp Med. 2003 Jun 16;197(12):1721-30 PMID: 12810690
  15. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
    J Clin Oncol. 2010 Jul 1;28(19):3167-75 PMID: 20516446
  16. Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity.
    Cancer Res. 2006 Apr 15;66(8):4450-60 PMID: 16618772
  17. A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells.
    J Immunol. 2007 Sep 15;179(6):4202-11 PMID: 17785860
  18. Role of lymphocyte activation gene-3 (Lag-3) in conventional and regulatory T cell function in allogeneic transplantation.
    PLoS One. 2014 Jan 27;9(1):e86551 PMID: 24475140
  19. PD-1 blockade induces responses by inhibiting adaptive immune resistance.
    Nature. 2014 Nov 27;515(7528):568-71 PMID: 25428505
  20. Lymphocyte activation gene-3 induces tumor regression and antitumor immune responses.
    Eur J Immunol. 1999 Dec;29(12):3867-76 PMID: 10601994
  21. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.
    Science. 1995 Nov 10;270(5238):985-8 PMID: 7481803
  22. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.
    Lancet. 2014 Sep 20;384(9948):1109-17 PMID: 25034862
  23. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
    N Engl J Med. 2012 Jun 28;366(26):2443-54 PMID: 22658127
  24. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.
    Science. 2014 May 9;344(6184):641-5 PMID: 24812403
  25. CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction.
    PLoS Pathog. 2012;8(8):e1002840 PMID: 22916009
  26. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.
    Immunity. 2007 Jul;27(1):111-22 PMID: 17629517
  27. IMP321 (sLAG-3) safety and T cell response potentiation using an influenza vaccine as a model antigen: a single-blind phase I study.
    Vaccine. 2007 Jun 11;25(24):4641-50 PMID: 17493710
  28. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells.
    Int Immunol. 2009 Sep;21(9):1065-77 PMID: 19651643
  29. PD-1 is a novel regulator of human B-cell activation.
    Int Immunol. 2013 Feb;25(2):129-37 PMID: 23087177
  30. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.
    N Engl J Med. 2008 Jun 19;358(25):2698-703 PMID: 18565862
  31. Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction.
    J Exp Med. 2003 May 5;197(9):1083-91 PMID: 12719480
  32. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation.
    J Exp Med. 2000 Jul 17;192(2):295-302 PMID: 10899916
  33. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.
    Nat Immunol. 2009 Jan;10(1):29-37 PMID: 19043418
  34. A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors.
    Cancer Lett. 2006 Apr 8;235(1):147-53 PMID: 15946792
  35. T cell exhaustion.
    Nat Immunol. 2011 Jun;12(6):492-9 PMID: 21739672
  36. Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis.
    Cancer Res. 2014 Jul 1;74(13):3441-53 PMID: 24780756
  37. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
    J Exp Med. 1995 Aug 1;182(2):459-65 PMID: 7543139
  38. The PD-1-PD-L pathway in immunological tolerance.
    Trends Immunol. 2006 Apr;27(4):195-201 PMID: 16500147
  39. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.
    J Clin Oncol. 2013 Nov 20;31(33):4199-206 PMID: 24127452
  40. Activation of human lymphocytes by a monoclonal antibody to B lymphoblastoid cells; molecular mass and distribution of binding protein.
    Cancer Immunol Immunother. 1995 Jun;40(6):376-82 PMID: 7627994
  41. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.
    Science. 2001 Jan 12;291(5502):319-22 PMID: 11209085
  42. Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3).
    Eur J Immunol. 2002 Aug;32(8):2255-63 PMID: 12209638
  43. Tyrosine phosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-associated adaptor complex AP-2.
    Immunity. 1997 May;6(5):583-9 PMID: 9175836
  44. Cutting edge: IFN-gamma enables APC to promote memory Th17 and abate Th1 cell development.
    J Immunol. 2008 Nov 1;181(9):5842-6 PMID: 18941172
  45. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.
    Blood. 2010 Sep 30;116(13):2286-94 PMID: 20460501
  46. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.
    J Exp Med. 2000 Jul 17;192(2):303-10 PMID: 10899917
  47. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.
    Clin Cancer Res. 2013 Mar 1;19(5):1021-34 PMID: 23460533
  48. PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice.
    J Clin Invest. 2010 Jul;120(7):2508-15 PMID: 20551512
  49. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.
    J Exp Med. 2010 Sep 27;207 (10 ):2187-94 PMID: 20819927
  50. Role of CXCR5 and CCR7 in follicular Th cell positioning and appearance of a programmed cell death gene-1high germinal center-associated subpopulation.
    J Immunol. 2007 Oct 15;179(8):5099-108 PMID: 17911595
  51. HTLV-1 specific CD8+ T cell function augmented by blockade of 2B4/CD48 interaction in HTLV-1 infection.
    PLoS One. 2014 Feb 05;9(2):e87631 PMID: 24505299
  52. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.
    Nat Med. 2003 May;9(5):562-7 PMID: 12704383
  53. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies.
    Clin Cancer Res. 2008 May 15;14(10):3044-51 PMID: 18483370
  54. MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial.
    J Transl Med. 2014 Apr 12;12:97 PMID: 24726012
  55. Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223).
    J Immunol. 2005 Jan 15;174(2):688-95 PMID: 15634887
  56. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.
    J Exp Med. 2009 Aug 3;206(8):1717-25 PMID: 19581407
  57. A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection.
    PLoS One. 2013 May 22;8(5):e63818 PMID: 23717490
  58. Restoring function in exhausted CD8 T cells during chronic viral infection.
    Nature. 2006 Feb 9;439(7077):682-7 PMID: 16382236
  59. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.
    Immunity. 1995 Nov;3(5):541-7 PMID: 7584144
  60. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
    N Engl J Med. 2013 Jul 11;369(2):134-44 PMID: 23724846
  61. Nivolumab in previously untreated melanoma without BRAF mutation.
    N Engl J Med. 2015 Jan 22;372(4):320-30 PMID: 25399552
  62. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.
    Immunity. 1999 Aug;11(2):141-51 PMID: 10485649
  63. Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation.
    PLoS Pathog. 2010 Jun 10;6(6):e1000947 PMID: 20548953
  64. Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients.
    J Clin Invest. 2011 Jun;121(6):2350-60 PMID: 21555851
  65. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells.
    J Exp Med. 2009 Dec 21;206(13):3015-29 PMID: 20008522
  66. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.
    J Immunol. 2003 Feb 1;170(3):1257-66 PMID: 12538684
  67. PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis.
    J Exp Med. 2013 Apr 8;210(4):757-74 PMID: 23530125
  68. Myeloid-derived suppressor cells regulate immune response in patients with chronic hepatitis B virus infection through PD-1-induced IL-10.
    J Immunol. 2014 Dec 1;193(11):5461-9 PMID: 25344470
  69. Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes.
    Eur J Immunol. 1994 Dec;24(12):3216-21 PMID: 7805750
  70. PD-L2 is a second ligand for PD-1 and inhibits T cell activation.
    Nat Immunol. 2001 Mar;2(3):261-8 PMID: 11224527
  71. The CD4-like molecule LAG-3, biology and therapeutic applications.
    Expert Opin Ther Targets. 2011 Jan;15(1):91-101 PMID: 21142803
  72. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.
    Cancer Res. 2012 Feb 15;72 (4):887-96 PMID: 22205715
  73. Cooperative B7-1/2 (CD80/CD86) and B7-DC costimulation of CD4+ T cells independent of the PD-1 receptor.
    J Exp Med. 2003 Jul 7;198(1):31-8 PMID: 12847135
  74. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.
    J Exp Med. 2000 Oct 2;192(7):1027-34 PMID: 11015443
  75. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells.
    Sci Transl Med. 2013 Aug 28;5(200):200ra116 PMID: 23986400
  76. First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity.
    J Transl Med. 2010 Jul 23;8:71 PMID: 20653948
  77. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression.
    Nature. 2006 Sep 21;443(7109):350-4 PMID: 16921384
  78. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
    J Clin Oncol. 2014 Apr 1;32(10):1020-30 PMID: 24590637
  79. PD-1 and its ligands in tolerance and immunity.
    Annu Rev Immunol. 2008;26:677-704 PMID: 18173375
  80. Molecular signature of CD8+ T cell exhaustion during chronic viral infection.
    Immunity. 2007 Oct;27(4):670-84 PMID: 17950003
  81. Programmed death ligand 2 in cancer-induced immune suppression.
    Clin Dev Immunol. 2012;2012:656340 PMID: 22611421
  82. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.
    Lancet Oncol. 2014 Jan;15(1):69-77 PMID: 24332512
  83. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells.
    Blood. 2008 Apr 1;111(7):3635-43 PMID: 18223165
  84. Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy.
    Oncoimmunology. 2013 Aug 1;2(8):e25961 PMID: 24083084
  85. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation.
    J Exp Med. 2014 May 5;211(5):781-90 PMID: 24778419
  86. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.
    J Clin Oncol. 2013 Dec 1;31(34):4311-8 PMID: 24145345
  87. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival.
    Cancer Immunol Res. 2013 Jul;1(1):54-63 PMID: 24416729
  88. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction.
    Nat Med. 2006 Oct;12(10):1198-202 PMID: 16917489
  89. Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection.
    Nat Immunol. 2011 Dec 11;13(2):188-95 PMID: 22157630
  90. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.
    Nature. 2014 Nov 27;515(7528):558-62 PMID: 25428503
  91. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.
    Cancer Res. 2005 Feb 1;65(3):1089-96 PMID: 15705911
  92. PD-1 expression on natural killer cells and CD8(+) T cells during chronic HIV-1 infection.
    Viral Immunol. 2012 Aug;25(4):329-32 PMID: 22742708
  93. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.
    Nat Med. 1999 Dec;5(12):1365-9 PMID: 10581077
  94. T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts.
    Eur J Cancer. 2001 Sep;37(13):1709-18 PMID: 11527700
  95. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application.
    Nat Immunol. 2013 Dec;14(12):1212-8 PMID: 24240160
  96. CD4⁺ follicular helper T cell infiltration predicts breast cancer survival.
    J Clin Invest. 2013 Jul;123(7):2873-92 PMID: 23778140
  97. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.
    Cancer Res. 2012 Feb 15;72(4):917-27 PMID: 22186141
  98. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands.
    J Immunol. 2008 Nov 15;181(10):6738-46 PMID: 18981091
  99. Programmed death ligand-1 expression in non-small cell lung cancer.
    Lab Invest. 2014 Jan;94(1):107-16 PMID: 24217091
  100. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.
    J Exp Med. 2010 Sep 27;207 (10 ):2175-86 PMID: 20819923
  101. Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma.
    J Immunol. 2013 May 1;190(9):4899-909 PMID: 23536636
  102. A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma.
    Clin Cancer Res. 2009 Oct 1;15(19):6225-31 PMID: 19755389
  103. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.
    Clin Cancer Res. 2014 Oct 1;20(19):5064-74 PMID: 24714771
  104. Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart.
    Circulation. 2007 Oct 30;116(18):2062-71 PMID: 17938288
  105. Inhibitory phenotype of HBV-specific CD4+ T-cells is characterized by high PD-1 expression but absent coregulation of multiple inhibitory molecules.
    PLoS One. 2014 Aug 21;9(8):e105703 PMID: 25144233
  106. PD-1 on dendritic cells impedes innate immunity against bacterial infection.
    Blood. 2009 Jun 4;113(23):5811-8 PMID: 19339692
  107. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.
    Sci Transl Med. 2012 Mar 28;4(127):127ra37 PMID: 22461641
  108. Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation.
    Eur J Immunol. 2006 Sep;36(9):2472-82 PMID: 16917960
  109. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis.
    Eur J Immunol. 2003 Nov;33(11):3117-26 PMID: 14579280
  110. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.
    Nat Med. 2002 Aug;8(8):793-800 PMID: 12091876
  111. On the role of the inhibitory receptor LAG-3 in acute and chronic LCMV infection.
    Int Immunol. 2010 Jan;22(1):13-23 PMID: 19880580
  112. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection.
    J Exp Med. 2008 Nov 24;205(12 ):2763-79 PMID: 19001139
  113. Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence.
    J Exp Med. 1984 Aug 1;160(2):521-40 PMID: 6332167
  114. Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo.
    J Immunol. 2004 May 1;172(9):5450-5 PMID: 15100286
  115. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems.
    J Clin Invest. 2007 Nov;117(11):3383-92 PMID: 17932562
  116. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.
    Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7 PMID: 12218188
  117. LAG-3, a novel lymphocyte activation gene closely related to CD4.
    J Exp Med. 1990 May 1;171(5):1393-405 PMID: 1692078
  118. B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis.
    J Immunol. 2002 Oct 1;169(7):3581-8 PMID: 12244148
  119. RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance.
    J Exp Med. 2014 May 5;211(5):943-59 PMID: 24752301
  120. Role of LAG-3 in regulatory T cells.
    Immunity. 2004 Oct;21(4):503-13 PMID: 15485628
  121. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
    N Engl J Med. 2012 Jun 28;366(26):2455-65 PMID: 22658128
  122. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells.
    J Exp Med. 2001 Apr 2;193(7):839-46 PMID: 11283156
  123. Acute depletion of activated memory B cells involves the PD-1 pathway in rapidly progressing SIV-infected macaques.
    J Clin Invest. 2010 Nov;120(11):3878-90 PMID: 20972331
Article Info
Journal
Nature reviews. Immunology
Abbr.
Nat Rev Immunol
ISSN
1474-1741
DOI
10.1038/nri3790
Published
2015-01-00
Pages
45-56
Language
English
Region
England
NLM ID
101124169
Subset
IM
External Links
PubMed source DOI: 10.1038/nri3790 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2